PolyPeptide Group AG (XSWX:PPGN) Inventories, Work In Process: CHF64.5 Mil (As of Dec. 2025)


XSWX:PPGN PolyPeptide Group AG XSWX:PPGN
69 GF Score
Price CHF45.55
GF Value CHF30.72
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Inventories, Work In Process?

PolyPeptide Group AG XSWX:PPGN -2.04% 69 Inventories, Work In Process is CHF64.5 Mil as of Dec. 2025. GuruFocus rates XSWX:PPGN with a GF Score™ of 69/100 and a GF Value™ of CHF30.72 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. PolyPeptide Group AG's work in process for the quarter that ended in Dec. 2025 was CHF64.5 Mil.

PolyPeptide Group AG Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Inventories, Work In Process Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial 53.29 50.74 35.00 42.21 64.55

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.00 0.00 42.21 0.00 64.55
XSWX:PPGN
69GF Score
PolyPeptide Group AG XSWX:PPGN
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of CHF64.5 Mil mean?
PolyPeptide Group AG (XSWX:PPGN) has a Inventories, Work In Process of CHF64.5 Mil as of Dec. 2025. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Inventories, Work In Process too high?
PolyPeptide Group AG's current Inventories, Work In Process is CHF64.5 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Inventories, Work In Process compare to ZTS and UTHR?
PolyPeptide Group AG's Inventories, Work In Process of CHF64.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Drug Manufacturers company?
A good Inventories, Work In Process depends on the Drug Manufacturers industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Inventories, Work In Process is CHF64.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF30.72, compared to a current price of CHF45.55 — trading 48.3% above its estimated fair value. The current Inventories, Work In Process is CHF64.5 Mil. PolyPeptide Group AG's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current Inventories, Work In Process is CHF64.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF45.55 is trading 48.3% above its estimated GF Value™ of CHF30.72. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for XSWX:PPGN:

  • Inventories, Work In Process: CHF64.5 Mil
  • GF Value™: CHF30.72 vs. price of CHF45.55 (48.3% above fair value)
  • GF Score™: 69/100 with 9 warning signs

No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
69GF Score

Get the complete analysis for XSWX:PPGN

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF45.55
Price
CHF30.72
GF Value